Global Breast Cancer Monoclonal Antibodies Market Size, Status, Research and Forecast 2019-2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 101

Report ID: 3745

Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protein stimulates the growth and division of malignant cells.
The breast cancer monoclonal antibodies (mAbs) market is one of the fastest-growing segments of the global mAbs market and has gained major research significance among biotech and pharmaceutical companies due to the presence of high unmet needs in this area. Antibodies are increasingly becoming the best choice to treat cancers, including breast cancer. The use of antibody-drug conjugates (ADCs),including radioimmunotherapy and antibody-directed enzyme prodrug therapy, is increasing rapidly. ADCs are highly effective cytotoxic drugs linked to mAbs. These drugs have shown to be potent and efficient in treating breast cancer. This has propelled vendors to focus on novel technologies such as Seattle Genetics (SGEN), ImmunoGen (IMGN), and Immunomedics (IMMU). The rising use of these antibodies in drug development increases revenue generation in the breast cancer mAbs market, contributing to market growth.
The breast cancer mAbs market in APAC will witness a high growth rate during the forecast period due to the better market penetration of breast cancer mAbs and biosimilars in emerging economies, especially in Japan, Australia, India, South Korea, and China. The rising number of initiatives undertaken by major vendors to assist patients in these countries is a significant contributor to the rise in sales of breast cancer mAbs in these countries. Moreover, the growing awareness about breast cancer and the available treatment alternatives will also propel growth prospects for the market growth in APAC.
In 2018, the global Breast Cancer Monoclonal Antibodies market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Breast Cancer Monoclonal Antibodies status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Breast Cancer Monoclonal Antibodies development in United States, Europe and China.

The key players covered in this study
Amgen
Roche
Mylan
Array BioPharma
Biocad
Boehringer Ingelheim
Bristol-Myers Squibb
Celldex Therapeutics
Celltrion
Daiichi Sankyo
GlaxoSmithKline
Immunomedics
MacroGenics
Merck
Novartis
Oncothyreon
Pfizer
Puma Biotechnology
Seattle Genetics
Sun Pharmaceutical Industries
Synta Pharmaceuticals
Teva Pharmaceuticals

Market segment by Type, the product can be split into
Naked MAbs
Conjugated MAbs

Market segment by Application, split into
Hospitals
Retail Pharmacies
Others

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Breast Cancer Monoclonal Antibodies status, future forecast, growth opportunity, key market and key players.
To present the Breast Cancer Monoclonal Antibodies development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Breast Cancer Monoclonal Antibodies are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Breast Cancer Monoclonal Antibodies Market Size Growth Rate by Type (2014-2025)
1.4.2 Naked MAbs
1.4.3 Conjugated MAbs
1.5 Market by Application
1.5.1 Global Breast Cancer Monoclonal Antibodies Market Share by Application (2014-2025)
1.5.2 Hospitals
1.5.3 Retail Pharmacies
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Breast Cancer Monoclonal Antibodies Market Size
2.2 Breast Cancer Monoclonal Antibodies Growth Trends by Regions
2.2.1 Breast Cancer Monoclonal Antibodies Market Size by Regions (2014-2025)
2.2.2 Breast Cancer Monoclonal Antibodies Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Breast Cancer Monoclonal Antibodies Market Size by Manufacturers
3.1.1 Global Breast Cancer Monoclonal Antibodies Revenue by Manufacturers (2014-2019)
3.1.2 Global Breast Cancer Monoclonal Antibodies Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Breast Cancer Monoclonal Antibodies Market Concentration Ratio (CR5 and HHI)
3.2 Breast Cancer Monoclonal Antibodies Key Players Head office and Area Served
3.3 Key Players Breast Cancer Monoclonal Antibodies Product/Solution/Service
3.4 Date of Enter into Breast Cancer Monoclonal Antibodies Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Breast Cancer Monoclonal Antibodies Market Size by Type (2014-2019)
4.2 Global Breast Cancer Monoclonal Antibodies Market Size by Application (2014-2019)

5 United States
5.1 United States Breast Cancer Monoclonal Antibodies Market Size (2014-2019)
5.2 Breast Cancer Monoclonal Antibodies Key Players in United States
5.3 United States Breast Cancer Monoclonal Antibodies Market Size by Type
5.4 United States Breast Cancer Monoclonal Antibodies Market Size by Application

6 Europe
6.1 Europe Breast Cancer Monoclonal Antibodies Market Size (2014-2019)
6.2 Breast Cancer Monoclonal Antibodies Key Players in Europe
6.3 Europe Breast Cancer Monoclonal Antibodies Market Size by Type
6.4 Europe Breast Cancer Monoclonal Antibodies Market Size by Application

7 China
7.1 China Breast Cancer Monoclonal Antibodies Market Size (2014-2019)
7.2 Breast Cancer Monoclonal Antibodies Key Players in China
7.3 China Breast Cancer Monoclonal Antibodies Market Size by Type
7.4 China Breast Cancer Monoclonal Antibodies Market Size by Application

8 Japan
8.1 Japan Breast Cancer Monoclonal Antibodies Market Size (2014-2019)
8.2 Breast Cancer Monoclonal Antibodies Key Players in Japan
8.3 Japan Breast Cancer Monoclonal Antibodies Market Size by Type
8.4 Japan Breast Cancer Monoclonal Antibodies Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Breast Cancer Monoclonal Antibodies Market Size (2014-2019)
9.2 Breast Cancer Monoclonal Antibodies Key Players in Southeast Asia
9.3 Southeast Asia Breast Cancer Monoclonal Antibodies Market Size by Type
9.4 Southeast Asia Breast Cancer Monoclonal Antibodies Market Size by Application

10 India
10.1 India Breast Cancer Monoclonal Antibodies Market Size (2014-2019)
10.2 Breast Cancer Monoclonal Antibodies Key Players in India
10.3 India Breast Cancer Monoclonal Antibodies Market Size by Type
10.4 India Breast Cancer Monoclonal Antibodies Market Size by Application

11 Central & South America
11.1 Central & South America Breast Cancer Monoclonal Antibodies Market Size (2014-2019)
11.2 Breast Cancer Monoclonal Antibodies Key Players in Central & South America
11.3 Central & South America Breast Cancer Monoclonal Antibodies Market Size by Type
11.4 Central & South America Breast Cancer Monoclonal Antibodies Market Size by Application

12 International Players Profiles
12.1 Amgen
12.1.1 Amgen Company Details
12.1.2 Company Description and Business Overview
12.1.3 Breast Cancer Monoclonal Antibodies Introduction
12.1.4 Amgen Revenue in Breast Cancer Monoclonal Antibodies Business (2014-2019)
12.1.5 Amgen Recent Development
12.2 Roche
12.2.1 Roche Company Details
12.2.2 Company Description and Business Overview
12.2.3 Breast Cancer Monoclonal Antibodies Introduction
12.2.4 Roche Revenue in Breast Cancer Monoclonal Antibodies Business (2014-2019)
12.2.5 Roche Recent Development
12.3 Mylan
12.3.1 Mylan Company Details
12.3.2 Company Description and Business Overview
12.3.3 Breast Cancer Monoclonal Antibodies Introduction
12.3.4 Mylan Revenue in Breast Cancer Monoclonal Antibodies Business (2014-2019)
12.3.5 Mylan Recent Development
12.4 Array BioPharma
12.4.1 Array BioPharma Company Details
12.4.2 Company Description and Business Overview
12.4.3 Breast Cancer Monoclonal Antibodies Introduction
12.4.4 Array BioPharma Revenue in Breast Cancer Monoclonal Antibodies Business (2014-2019)
12.4.5 Array BioPharma Recent Development
12.5 Biocad
12.5.1 Biocad Company Details
12.5.2 Company Description and Business Overview
12.5.3 Breast Cancer Monoclonal Antibodies Introduction
12.5.4 Biocad Revenue in Breast Cancer Monoclonal Antibodies Business (2014-2019)
12.5.5 Biocad Recent Development
12.6 Boehringer Ingelheim
12.6.1 Boehringer Ingelheim Company Details
12.6.2 Company Description and Business Overview
12.6.3 Breast Cancer Monoclonal Antibodies Introduction
12.6.4 Boehringer Ingelheim Revenue in Breast Cancer Monoclonal Antibodies Business (2014-2019)
12.6.5 Boehringer Ingelheim Recent Development
12.7 Bristol-Myers Squibb
12.7.1 Bristol-Myers Squibb Company Details
12.7.2 Company Description and Business Overview
12.7.3 Breast Cancer Monoclonal Antibodies Introduction
12.7.4 Bristol-Myers Squibb Revenue in Breast Cancer Monoclonal Antibodies Business (2014-2019)
12.7.5 Bristol-Myers Squibb Recent Development
12.8 Celldex Therapeutics
12.8.1 Celldex Therapeutics Company Details
12.8.2 Company Description and Business Overview
12.8.3 Breast Cancer Monoclonal Antibodies Introduction
12.8.4 Celldex Therapeutics Revenue in Breast Cancer Monoclonal Antibodies Business (2014-2019)
12.8.5 Celldex Therapeutics Recent Development
12.9 Celltrion
12.9.1 Celltrion Company Details
12.9.2 Company Description and Business Overview
12.9.3 Breast Cancer Monoclonal Antibodies Introduction
12.9.4 Celltrion Revenue in Breast Cancer Monoclonal Antibodies Business (2014-2019)
12.9.5 Celltrion Recent Development
12.10 Daiichi Sankyo
12.10.1 Daiichi Sankyo Company Details
12.10.2 Company Description and Business Overview
12.10.3 Breast Cancer Monoclonal Antibodies Introduction
12.10.4 Daiichi Sankyo Revenue in Breast Cancer Monoclonal Antibodies Business (2014-2019)
12.10.5 Daiichi Sankyo Recent Development
12.11 GlaxoSmithKline
12.12 Immunomedics
12.13 MacroGenics
12.14 Merck
12.15 Novartis
12.16 Oncothyreon
12.17 Pfizer
12.18 Puma Biotechnology
12.19 Seattle Genetics
12.20 Sun Pharmaceutical Industries
12.21 Synta Pharmaceuticals
12.22 Teva Pharmaceuticals

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details